Illexcor Therapeutics, a Richmond, VA-based biopharmaceutical firm growing new oral therapies for sickle cell illness (SCD), acquired an funding from Zynext Ventures.
The quantity of the deal was not disclosed.
The corporate intends to make use of the funds to broaden operations and its improvement efforts.
Led by CEO Andrew Fleischman, Illexcor Therapeutics is a biopharmaceutical firm targeted on the invention and improvement of revolutionary oral therapies for sickle cell illness. Their lead asset is a drug designed to instantly goal the basis explanation for SCD, providing the potential for vital disease-modifying medical advantages.
Commenting on the information, Andrew Fleischman mentioned: “We’re excited to accomplice with Zynext Ventures to advance our lead drug ILX002 into medical trials later this yr. We’re hopeful that ILX002 might be a transformative therapy not just for SCD sufferers within the U.S. but in addition for hundreds of thousands across the globe. Zynext Ventures and Zydus Lifesciences are in a strategic place to assist us obtain these targets.”
FinSMEs
12/03/2025
